The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, in patients with pancreatic cancer and other CA19-9 positive malignancies.
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Aduro Biotech; Agios (I); ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); Blueprint Medicines (I); Boston Scientific (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CASI Pharmaceuticals (I); Celgene; Celsion (I); Delcath Systems (I); Eisai (I); Gilead Sciences; Halozyme (I); IntegraGen (I); Ipsen (I); Janssen; MedImmune; Merck (I); Merrimack; New B Innovation (I); Newlink Genetics; Onxeo (I); Sanofi; Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); VAXIMM; Vicus Therapeutics; Westhaven (I)
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Mabvax (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst)
 
Judy Sing-Zan Wang
No Relationships to Disclose
 
Kenneth H. Yu
Consulting or Advisory Role - celgene; Merck Serono; Merrimack
 
Maeve Aine Lowery
Consulting or Advisory Role - Agios; Celgene
 
Anna M. Varghese
Consulting or Advisory Role - Cancer Genetics (I); Sequenom (I)
Research Funding - BioMed Valley Discoveries (Inst); Lilly (Inst); Verastem (Inst)
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Sanofi (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
Erkut Hasan Borazanci
Consulting or Advisory Role - Bayer; Biogen (I); Fujifilm; Genzyme (I); Merrimack; Novartis (I); Teva (I)
Speakers' Bureau - Biogen (I); Celgene; Genzyme (I); Merrimack; Novartis (I); Taiho Pharmaceutical; Teva (I)
 
Hayley Estrella
Employment - MabVax
 
Kimberly Fowler
Employment - MabVax
 
Mariella Hoskin
Employment - MabVax
 
H. Toni Jun
Employment - MabVax
Leadership - MabVax
 
Teresa J. Melink
Employment - SciQuus Oncology
Leadership - SciQuus Oncology
Stock and Other Ownership Interests - SciQuus Oncology
 
Paul Maffuid
Employment - MabVax
Leadership - MabVax
Stock and Other Ownership Interests - MabVax
 
Pamela Klein
No Relationships to Disclose
 
John Gutheil
Employment - SciQuus Oncology
Stock and Other Ownership Interests - SciQuus Oncology
Travel, Accommodations, Expenses - SciQuus Oncology
 
Todd Michael Bauer
Employment - Sarah Cannon Research Institute; Tennessee Oncology
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immunogen (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); medpacto (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Principa Biopharma (Inst); Stemline Therapeutics (Inst)